TO THE EDITOR
Extramedullary infiltration complicating the clinical course of acute promyelocytic leukemia (APL) has been frequently reported in recent years, with most commonly involved sites being skin and CNS.
1 Some authors hypothesized a role for ATRA in extramedullary disease (EMD) localization 2 although this hypothesis has been questioned in a large study recently reported by the Italian GIMEMA group. 3 We report a patient with APL who underwent third relapse after allogeneic transplantation with multiple EMD localizations including the scalp and breast.
A 38-year-old woman who had been treated in 1995 with radiotherapy and surgery for right breast cancer presented in November 1997 with clinically suspected APL. Diagnosis was confirmed by cytogenetic and RT-PCR demonstration of t(15;17) and PML/RARa hybrid gene, respectively, in bone marrow blasts. 1 month before APL diagnosis the patient had underwent coronary thrombolysis because of myocardial infarction. In light of her recent clinical history, induction treatment was started with ATRA 45 mg/m 2 until hematologic complete remission (HCR) and hydroxyurea 6 g/day for 15 days. Molecular and HCR was documented at day þ 30, and the patient received three polychemotherapy consolidation courses according to the GIMEMA protocol AIDA0493 followed by a maintenance schedule with ATRA 45 mg/m 2 /day for 15 days every 3 months.
4
After 9 months of maintenance therapy (April 99) the patient developed pericarditis and ATRA was discontinued. After 3 months, because of hematologic relapse she was treated with oral ATRA for 30 days followed by four daily courses of chemotherapy with cytarabine 1 g/m 2 /day and mitoxantrone 6 mg/m 2 /day obtaining a second molecular remission (MR). In October 1999 the patient underwent autologous transplantation and remained in second MR until April 2000, when a new molecular relapse was documented during routine molecular monitoring. She was then treated with idarubicin 12 mg/m 2 (days 2, 4, 6, 8) and ATRA 45 mg/m 2 /day obtaining a new shortlived MR. In August 2000 RT-PCR of PML/RARa showed a new molecular relapse and in September 2000 the patient received allogeneic bone marrow transplantation obtaining a fourth MR that lasted 3 years. In September 2003 she presented with bone marrow molecular relapse and a scalp nodule. Fine needle aspiration of the nodule revealed atypical promyelocytes displaying the characteristic microspeckled APL pattern by immunostaining with an anti-PML monoclonal antibody. 5 The patient was treated for fourth marrow molecular relapse with gemtuzumab-ozogamicin (GO) at 6 mg/m 2 for two doses and local radiotherapy for the scalp lesion obtaining a complete disappearance of the nodule and a new MR in the bone marrow. In March 2004, fifth molecular relapse was documented in the marrow upon molecular monitoring. Moreover, the biopsy specimens of the scar region of the previous nodule and of a new lesion in the nearby scalp region resulted positive for the PML-RARa fusion mRNA. The patient was then treated with two successive donor lymphocyte infusions and a new course of radiotherapy obtaining again MR in the marrow. In July 2004 because of the appearance of a breast lesion below the previous tumor surgery scar, the patient was again admitted for diagnostic studies to the hematology unit. Fine needle biopsy of the breast nodule and microscopic examination showed infiltration by abnormal promyelocytes, while RT-PCR of a bone marrow sample revealed concomitant molecular relapse. At time of the present report, the patient is being treated with intravenous arsenic trioxide (ATO) 10 mg/day. Although the use of ATRA has been hypothesized as a possible pathogenetic mechanism to explain the apparent increase of EMD in APL, this phenomenon may simply reflect a prolonged risk exposure due to improved survival of patients in the ATRA era.
3 ATRA has been shown to stimulate APL cells to express intercellular adhesion molecules (ICAM-1) which in turn may be associated with the pathophysiology of EMD in APL. 6 In addition, other investigators suggested that tissue injury caused by diagnostic procedures may represent a predisposing mechanism favoring the occurrence of EMD in APL. 7 In our patient, EMD localized in the scalp and under the breast tumor surgery scar, and it was always detected in association with a simultaneous bone marrow molecular relapse, as detected by PCR. It is worth noting that bone marrow involvement has been detected in association with EMD in the majority of cases in which PCR studies were carried out. This observation, combined with the close concomitance of EMD and bone marrow relapse hereby observed, suggests that EMD relapse should always be regarded as systemic disease and treated accordingly. As to APL localization in the breast, a medline search led us to identify only one single case reported to date.
8 To the best of our knowledge, however, our's is the first description of breast APL localization in a patient with previous cancer in the same site. Both the FLT3-ITD and FLT3-D835 mutations result in constitutive activation of the receptor that probably confers a proliferative benefit to AML cells with ligand-independent dimerization, autophosphorylation and activation of downstream pathways. As FLT3 mutations have been implicated in the pathogenesis of AML and are potential therapeutic targets for specific tyrosine kinase inhibitors, a complete characterization of FLT3 mutations would be necessary.
FLT3-D835/I836 mutations were intensively examined by restriction fragment length polymorphism-mediated PCR assay using EcoRV.
1 However, this screening cannot detect other mutations in the activation loop of the FLT3 gene. In this study, we searched for novel mutations in the activation loop of the FLT3 gene in 172 untreated patients with de novo AML using nonisotopic RNase cleavage assay (NIRCA). Informed consent to use the samples for this study was obtained from each patient according to guidelines based on the tenets of the revised Helsinki Protocol by the Institutional Committees for the Protection of Human Subjects and Analysis of the Human Genome. Total cellular RNA was extracted from mononuclear cells by TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). cDNA was synthesized using total RNA and Oligo(dT) 12-18 primer with SuperScript II reverse transcriptase (Invitrogen). cDNA was amplified by PCR using primers FLTK2-S, 5 0 -TCAAATCTCAGGGCTTCATGGG-3 0 (GenBank accession number Z26652: 2250-2271) and FLTK2-A, 5
0 -AGAGAGTAGC CCCAAATCCATC-3 0 (2955-2934) to cover the activation loop in the TK2 domain (Figure 1a) . A 1/50 aliquot of the first PCR solution was used to seed the second round of PCR with a new set of primers tagged with the 20-base T7 promoter sequence, T7-FLK-2S, 5 0 -TAATACGACTCACTATAGGGAGTCGTGTGTTC ACAGAGAC-3 0 (2414-2433) and T7-FLK-A, 5 0 -TAATACGACTC ACTATAGGGTCTGCTGAAAGGTCGCCTGT-3 0 (2931-2912). NIRCA was performed using the MutationScreener Kit (Ambion, Austin, TX, USA). The second PCR products were converted to RNA by transcription with T7 polymerase. Each RNA strand was hybridized with the transcript from the wild-type cDNA, cleaved with RNase1, and electrophoresed in 2.5% agarose gels. The NIRCA could detect a single-base mutation in the TK2 domain of the FLT3 gene when leukemic cells carrying a mutation were present in 5% of the test samples ( Supplementary  Figure 1) . To ascertain whether the mutations were at D835 or I836, the second PCR products were digested by EcoRV (TaKaRa, Otsu, Japan) and subjected to electrophoresis, as described previously.
3 For sequencing, cDNA was amplified by PCR to produce 480 bp products using primers FL-MF4, 5 0 -CAA ATTCCAGCATGCCTGGTTCA-3 0 (2198-2220), and FL-MR2, 5 0 -GAATGCCAGGGTAAGGATTCACA-3 0 (2677-2655). The PCR products were subcloned into plasmid pGEM-T Easy vector (Promega Co, Madison, WI, USA) and subjected to cycle sequencing (Applied Biosystems, Foster City, CA, USA).
Of 172 patients with newly diagnosed AML examined for activating loop mutations in the FLT3 gene by NIRCA, 16 (9.3%) showed positive results. For patients with positive results, the reproducibility of NIRCA was confirmed by experiments performed at least twice. Subsequently, we performed EcoRV digestion of the NIRCA-positive-PCR products. A total of 15 patients generated nondigested band and confirmed the presence of the mutations at D835 or I836 by sequencing. One patient with M2 and t(8;21) showed positive for NIRCA (Figure 1b) , and negative for EcoRV digestion (Figure 1c ). RT-PCR was repeated using different cDNA from this patient, and gave the same results.
